This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy
Virology Journal Open Access 22 April 2022
-
AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation
Molecular Cancer Open Access 31 July 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. First oncolytic virus edges towards approval in surprise vote. Nat Biotechnol 33, 569–570 (2015). https://doi.org/10.1038/nbt0615-569
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0615-569
This article is cited by
-
Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy
Gene Therapy (2023)
-
A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy
Virology Journal (2022)
-
Viruses as tools in gene therapy, vaccine development, and cancer treatment
Archives of Virology (2022)
-
The changing landscape of clinical trial and approval processes in China
Nature Reviews Clinical Oncology (2017)
-
Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses
Molecular Therapy - Methods & Clinical Development (2016)